Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
EXCALIBER-RRMM: A phase 3, two-stage trial of iberdomide, daratumumab, dexamethasone (IberDd) versus daratumumab, bortezomib, dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma
Sagar Lonial, MD, FACP
Professor and Chair
Emory University School of Medicine, Atlanta, GA, USA
Atlanta, Georgia, United States